23,5 million euro for a cutting-edge allergy treatment

May 19, 2016 News BioVox

ASIT Biotech, a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, announced the results of its IPO of new shares. The company raised € 23.5 million in new capital at a final offer price of € 7.00 per share and initial market capitalization of € 89.3 million. This allows ASIT to further develop their current product pipeline, to cover general corporate purposes and to accelerate the discovery of product candidates for the new ASIT+™ platform.

The exciting new ASIT+TM technology platform relies on the administration of only 4 sequential immunizations of patients who suffer from hay fever, guaranteeing protection during an entire year. Currently, the 25 million people in Europe who experience hay fever and who need to protect themselves during the pollen season (mid May-late August) must take daily anti-allergenic pills or injections. ASIT Biotech innovation therapy is meant to result in a short treatment, expected to improve patient compliance and daily-life effectiveness.


BioVox
BioVox

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts